These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1924427)

  • 1. Antibodies to tumour necrosis factor in the treatment of severe sepsis: rationale and early clinical experience.
    Cohen J
    Prog Clin Biol Res; 1991; 367():187-96. PubMed ID: 1924427
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapies for sepsis. Emerging therapies for sepsis and septic shock.
    Abraham E
    West J Med; 1997 Mar; 166(3):195-200. PubMed ID: 9143195
    [No Abstract]   [Full Text] [Related]  

  • 3. Macrophage migration inhibitory factor (MIF) modulates innate immune responses induced by endotoxin and Gram-negative bacteria.
    Roger T; Glauser MP; Calandra T
    J Endotoxin Res; 2001; 7(6):456-60. PubMed ID: 11753217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytokines and septic shock. New perspectives on its treatment].
    Zamora Madaria E
    An Med Interna; 1993 Dec; 10(12):573-5. PubMed ID: 8049320
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent developments in our understanding of sepsis: evaluation of anti-endotoxin antibodies and biological response modifiers.
    Talan DA
    Ann Emerg Med; 1993 Dec; 22(12):1871-90. PubMed ID: 8239111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of severe sepsis and septic shock--are antibiotics the only remedy to treat infections?].
    Złotorowicz M
    Przegl Epidemiol; 2001; 55 Suppl 3():81-4. PubMed ID: 11984966
    [No Abstract]   [Full Text] [Related]  

  • 7. [Monoclonal antibodies in the treatment of septic shock].
    Trilla A; Alonso P
    Med Clin (Barc); 1992 Dec; 99(20):778-80. PubMed ID: 1460950
    [No Abstract]   [Full Text] [Related]  

  • 8. Passive immunotherapy of gram-negative bacteremia, sepsis and septic shock.
    Spapen HD; Diltoer M; Huyghens LP
    Acta Clin Belg; 1993; 48(1):20-9. PubMed ID: 7684546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monoclonal antibodies in the treatment of sepsis caused by Gram-negative microorganisms].
    Otero AJ; Linares M
    Rev Cubana Med Trop; 1998; 50(1):31-5. PubMed ID: 9842265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New strategies in nonantibiotic treatment of gram-negative sepsis.
    Cohn J; Bone RC
    Cleve Clin J Med; 1992; 59(6):608-15. PubMed ID: 1424072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mediators of septic shock: new approaches for interrupting the endogenous inflammatory cascade.
    Giroir BP
    Crit Care Med; 1993 May; 21(5):780-9. PubMed ID: 8482101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety evaluation for a cell-based immune support system in an ex vivo rat model of gram-negative sepsis.
    Sauer M; Altrichter J; Kreutzer HJ; Schmidt H; Nöldge-Schomburg G; Schmidt R; Mitzner SR
    Ther Apher Dial; 2009 Oct; 13(5):444-50. PubMed ID: 19788463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of gram-negative septic shock with an immunoglobulin.
    Werdan K; Pilz G
    Crit Care Med; 1992 Sep; 20(9):1364-5. PubMed ID: 1521458
    [No Abstract]   [Full Text] [Related]  

  • 14. Epidemiology, pathophysiology and clinical presentation of gram-negative sepsis.
    Hazinski MF; Iberti TJ; MacIntyre NR; Parker MM; Tribett D; Prion S; Chmel H
    Am J Crit Care; 1993 May; 2(3):224-35; quiz 236-7. PubMed ID: 8364674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial.
    Wortel CH; Dellinger RP
    Crit Care Med; 1993 Jan; 21(1):163-5. PubMed ID: 8420724
    [No Abstract]   [Full Text] [Related]  

  • 16. Experimental study of extracorporeal perfusion for septic shock.
    Sato T; Orlowski JP; Zborowski M
    ASAIO J; 1993; 39(3):M790-3. PubMed ID: 8268646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis].
    van Deventer SJ; van der Linden CJ; Roord JJ; Schellekens H; Schellekens JF
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):334-6. PubMed ID: 8437630
    [No Abstract]   [Full Text] [Related]  

  • 18. Sepsis and SIRS.
    Bone RC
    Nephrol Dial Transplant; 1994; 9 Suppl 4():99-103. PubMed ID: 7800276
    [No Abstract]   [Full Text] [Related]  

  • 19. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha).
    Hinshaw LB; Tekamp-Olson P; Chang AC; Lee PA; Taylor FB; Murray CK; Peer GT; Emerson TE; Passey RB; Kuo GC
    Circ Shock; 1990 Mar; 30(3):279-92. PubMed ID: 2178801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possibilities of immunoprophylaxis and immunotherapy in gut-derived infectious-toxic shock (GITS).
    Imbach P; Hässig A; Cottier H
    Curr Stud Hematol Blood Transfus; 1992; (59):301-23. PubMed ID: 1572217
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.